Latest Clinical News

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia (08-22-2017)

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children... Continue Reading

U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial (08-21-2017)

CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has... Continue Reading

Cervical Cancer Survivors Frequently Suffer From Long-Term Side Effects of Treatment (08-17-2017)

According to a new study around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue or hot flushes.1 Cervical cancer affects more than 500,000 women around the world each year with an average... Continue Reading

Alternative Medicine Used Alone Appears to Reduce Survival Rates in Cancer Patients (08-16-2017)

Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center... Continue Reading

Head and Neck Cancer-What You Need to Know (08-14-2017)

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000... Continue Reading

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia (08-10-2017)

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic,... Continue Reading

Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma (08-9-2017)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent... Continue Reading

Roadmap to Personalized Therapies for Sarcoma and other Aggressive Cancers (08-8-2017)

Sarcoma is a rare and deadly form of cancer occurring in the bones and connective tissue that affects individuals of all ages. Its aggressiveness, rarity and diversity continue to hinder efforts to identify effective therapies for people with this malignancy.... Continue Reading

FDA Approves Vyxeos for Adults with Poor Prognosis AML (08-7-2017)

The U.S. Food and Drug Administration granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes... Continue Reading

Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers (08-2-2017)

Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric... Continue Reading

Nipple-Sparing Mastectomy Has Low Rate of Breast Cancer Recurrence (08-1-2017)

Investigators say most women with breast cancer are eligible for this type of mastectomy, which leaves the natural nipple in place Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the... Continue Reading

Balance and Gait is Negatively Impacted By Chemotherapy Treatment (07-26-2017)

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State... Continue Reading

Next Page »